Immupharma News - IMM

Best deals to access real time data!
Real-time Level 1 for London Stock Exchange
Monthly Subscription
for only
$26.87
London Stock Exchange Level 2
Monthly Subscription
for only
$70.55
Real-time Level 1 for London Stock Exchange + FTSE
Monthly Subscription
for only
$80.63
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Immupharma IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  +2.5 +2.62% 98 99.75 96.25 99.75 95.5 11:35:29
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Recent News

Date Time Source Heading
11/02/201705:09ALNCImmuPharma Phase III Lupuzor Trial On Track As 58% Complete..
11/02/201703:34ALNC*Lupuzor Sees Continued "Robust" Safety Record In Phase III..
11/02/201703:00UKREGImmupharma PLC Update on LupuzorT Pivotal Phase III Study
10/16/201710:29UKREGImmupharma PLC Holding(s) in Company
10/04/201705:53ALNCImmuPharma Nets Over GBP5.0 Million In Completed Lanstead..
10/04/201702:00UKREGImmupharma PLC Completion of Lanstead Sharing Agreement
9/27/201706:10ALNCImmuPharma Focused On Lupuzor Development As Interim Loss..
9/27/201702:00UKREGImmupharma PLC Interim Results
9/26/201704:56ALNCImmuPharma Prepares Regulatory Filings Ahead Of Lupuzor..
9/26/201702:00UKREGImmupharma PLC Preparation of Lupuzor'sT Regulatory..
9/21/201705:57ALNCImmupharma Confident As Phase III Lupuzor Trial On Track
9/21/201702:00UKREGImmupharma PLC Update on LupuzorT Pivotal Phase III Study
9/19/201702:01UKREGImmupharma PLC Notification of Interim Results
8/18/201712:09UKREGImmupharma PLC AIM Rule 17 Notice
7/12/201706:00UKREGImmupharma PLC Grant of Options
6/30/201707:04UKREGImmupharma PLC Result of AGM
6/30/201706:49ALNCImmuPharma Recruits And Doses 200 Patients In Phase III..
6/30/201702:00UKREGImmupharma PLC Update on LupuzorT Pivotal Phase III Study
6/07/201702:01UKREGImmupharma PLC Annual Report & Notice of AGM
6/01/201706:05ALNCImmuPharma 2016 Loss Widens As It Progresses Lupus Phase III..
6/01/201702:00UKREGImmupharma PLC Final Results
5/22/201702:01UKREGImmupharma PLC Notification of Full Year Results
5/17/201704:30ALNCImmuPharma On Track For Lupuzor Top-Line Data In First..
5/17/201702:00UKREGImmupharma PLC Update on Lupuzor Phase III Study
3/31/201705:17UKREGImmupharma PLC New Employee Share Option Plan & Grant of..
3/31/201703:33UKREGImmupharma PLC New Employee Share Option Plan & Grant of..
3/24/201703:01RNSNONImmupharma PLC ImmuPharma to present at Master Investor Show
3/22/201704:51UKREGImmupharma PLC Holding(s) in Company
3/20/201707:41UKREGImmupharma PLC Holding(s) in Company
3/20/201706:51ALNCLegal & General Raises Stake In ImmuPharma To 3.4% In..
3/20/201703:01UKREGImmupharma PLC Holding(s) in Company
3/10/201711:00ALNCUPDATE: ImmuPharma Raises GBP4.1 Million, Seeks Partners For..
3/10/201710:52UKREGImmupharma PLC £4.1 Million Fund Raise via Accelerated..
3/10/201704:54ALNCImmuPharma To Raise GBP3 Million As It Seeks Partners For..
3/10/201702:00UKREGImmupharma PLC Accelerated Bookbuild for the Issue of Equity
3/06/201710:55UKREGImmupharma PLC Holding(s) in Company
2/17/201709:04UKREGImmupharma PLC Holding(s) in Company
1/25/201706:22PRNUSImmuPharma PLC: Update on Lupuzorâ„¢ Pivotal Phase III Study..
1/25/201705:57ALNCImmuPharma To Report Top-Line Results From Lupuzor Trial In..
1/25/201702:00UKREGImmupharma PLC Update on Lupuzor Phase III Study
1/24/201702:00UKREGImmupharma PLC Change of Adviser
12/29/201605:54UKREGImmupharma PLC Holding(s) in Company
12/22/201603:47ALNCImmuPharma Completes Patient Recruitment For Lupuzor Trial
12/22/201602:00UKREGImmupharma PLC Update on Lupuzor Pivotal Phase III Study
See more news about this stock »
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20171117 19:35:35